“Inhibition”的搜索结果，显示 51-60 项，共有 1251 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®). Tissue ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies. Rochester, Minn. The purpose of this study is to determine the safety and ...

3. 肾病和高血压- 临床试验- 妙佑医疗国际

   ... inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient is post renal transplantation ...

4. 胃肠病科和肝病科- 临床试验- 妙佑医疗国际

   The purpose of this study is: To assess the efficacy of treatment with checkpoint inhibitors (Pembrolizumab or Nivolumab) in metastatic gastric and esophageal ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The purpose of this study is: To assess the efficacy of treatment with checkpoint inhibitors (Pembrolizumab or Nivolumab) in metastatic gastric and esophageal ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor ... PARP inhibitors are a type of ...

7. 肺癌计划- 临床试验- 妙佑医疗国际

   ... inhibitor (CPI, generally refers to anti-PD(L)1 antibodies) treatment, CPI-naïve hepatocellular carcinoma (HCC), and treatment-naïve endometrioid ...

8. 妙佑医疗国际 - 多发性硬化症的新兴治疗方法

   Torke S, et al. Inhibition of Bruton's tyrosine kinase as a novel therapeutic approach in multiple sclerosis. Expert Opinion on Investigational Drugs. 2020 ...

9. Untitled

   Page 1.

10. 肾病和高血压- 临床试验- 妙佑医疗国际

    ... inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient is post renal transplantation ...